Ferdinandos Skoulidis

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-4676-4503

发表论文 461 篇 · 总被引 17988 次 · h-index 46

代表论文

• Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 , KEAP1 , and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study. (2026 · Journal of Clinical Oncology · 被引 1)
• First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non–small cell lung cancer (NSCLC): Results from the Krascendo-170 study. (2026 · Journal of Clinical Oncology · 被引 1)
• Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT) (2026 · Clinical Cancer Research)
• PP01.43: Machine Learning-Guided Treatment Selection for KRAS-Altered and Wild-Type Metastatic Non-Squamous Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)
• Supplementary Figure S1 from Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer (2026)
• Supplementary Figure S10 from Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer (2026)